J Cancer 2017; 8(8):1492-1497. doi:10.7150/jca.18615

Research Paper

Prediction of Lymph Node Metastases in Gastric Cancer by Serum APE1 Expression

Xi Wei1*, Yi-bo Li3*, Ying Li2, Ben-cheng Lin8, Xiao-Min Shen4, Ran-Liang Cui5, Ya-Jun Gu6, Ming Gao7, Yue-Guo Li5✉, Sheng Zhang1✉

1. Department of Diagnostic and Therapeutic Ultrasonography, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China;
2. The Third Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China;
3. Department of general surgery, The first affiliated hospital of DaLian medical university;
4. Department of Clinical Laboratory, Tianjin second people' hospital;
5. Department of Clinical Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China;
6. School of Medical Laboratory, Tianjin Medical University;
7. Department of Thyroid and Cervical Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China;
8. Tianjin Institute of Health and Environmental Medicine, Key Laboratory of Risk Assessment and Control Technology for Environment & Food Safety, Tianjin 300050, China.
* Xi Wei and Yi-bo Li contributed equally to this work.

Abstract

Aims: To investigate the functional role of serum Human apurinic/apyrimidinic endonuclease 1 (APE1) in prediction of lymph node metastasis in gastric cancer patients.

Materials and methods: Serum samples were pre-operational collected from 86 patients with gastric cancer from Tianjin Medical University Cancer Institute and Hospital from March 2016 to August 2016. The serum of APE1 was measured by ELISA development kit and other CA242, CA724, CA199 and CEA levels by electrochemiluminescence assay.

Results: The total of 86 patients with gastric cancer was classified into two groups (lymph node positive and negative groups). Using ELISA assay, we found out that the concentration of serum APE1 was higher in lymph node positive group than that of lymph node negative group. The receiver operating characteristic (ROC) curve was performed to analyze, indicating that area under the ROC curve of serum APE1 were better than those of each regular markers (CEA+CA199+CA242+CA724) or combination of these markers. Additionally, the APE1 overexpression was uncovered in tissue of gastric cancer patients with lymph nodes metastases, which is correlation with results of serum APE1.

Conclusion: Serum APE1 was identified as a valuable marker for prediction of lymph node metastases in patients with gastric cancer.

Keywords: APE1, Gastric cancer, lymph node involvement, serum, marker.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Wei X, Li Yb, Li Y, Lin Bc, Shen XM, Cui RL, Gu YJ, Gao M, Li YG, Zhang S. Prediction of Lymph Node Metastases in Gastric Cancer by Serum APE1 Expression. J Cancer 2017; 8(8):1492-1497. doi:10.7150/jca.18615. Available from http://www.jcancer.org/v08p1492.htm